Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome

Leukemia Research

Volumn 32, Issue 4, 2008, Pages 553-558

  Yue, Gang ^a   Hao, Suyang ^a   Fadare, Oluwole ^b   Baker, Stephen ^a   Pozdnyakova, Olga ^a   Galili, Naomi ^a   Woda, Bruce A ^a   Raza, Azra ^a   Wang, Sa A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Cytogenetics; Hypocellular; IPSS risk groups; Myelodysplastic syndrome; Survival

Indexed keywords

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; CYTOGENETICS; HUMAN; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL; THROMBOCYTOPENIA;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BONE MARROW; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INCIDENCE; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SURVIVAL RATE;

EID: 39149083040     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.08.006     Document Type: Article

References (23)

1. Claessens Y.E., Bouscary D., Dupont J.M., Picard F., Melle J., Gisselbrecht S., et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 99 (2002) 1594-1601
2. Goyal R., Qawi H., Ali I., Dar S., Mundle S., Shetty V., et al. Biologic characteristics of patients with hypocellular myelodysplastic syndromes. Leuk Res 23 (1999) 357-364
3. Mundle S.D., Venugopal P., Cartlidge J.D., Pandav D.V., Broady-Robinson L., Gezer S., et al. Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood 88 (1996) 2640-2647
4. Raza A., Gezer S., Mundle S., Gao X.Z., Alvi S., Borok R., et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86 (1995) 268-276 [see comment]
5. Mangi M.H., and Mufti G.J. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. Blood 79 (1992) 198-205
6. Nand S., and Godwin J.E. Hypoplastic myelodysplastic syndrome. Cancer 62 (1988) 958-964
7. Vardiman J. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program (2006) 199-204
8. Marisavljevic D., Cemerikic V., Rolovic Z., Boskovic D., and Colovic M. Hypocellular myelodysplastic syndromes: clinical and biological significance. Med Oncol 22 (2005) 169-175
9. Maschek H., Kaloutsi V., Rodriguez-Kaiser M., Werner M., Choritz H., Mainzer K., et al. Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. Ann Hematol 66 (1993) 117-122
10. Tuzuner N., Cox C., Rowe J.M., Watrous D., and Bennett J.M. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol 91 (1995) 612-617 [see comment]
11. Saad S.T., Vassallo J., Arruda V.A., and Lorand-Metze I. The role of bone marrow study in diagnosis and prognosis of myelodysplastic syndrome. Pathologica 86 (1994) 47-51
12. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann. Oncol. 1999;10:1419-32.
13. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H., et al. Cox C: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87 (1994) 746-754 [see comment]
14. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88. [see comment] [erratum appears in Blood 1998 Feb 1;91(3):1100].
15. Tuzuner N., Cox C., Rowe J.M., and Bennett J.M. Bone marrow cellularity in myeloid stem cell disorders: impact of age correction. Leuk Res 18 (1994) 559-564
16. Mitelman F. An International System for Human Cytogenetic Nomenclature (1995), CT, Karger, Basel, Farmington
17. Fohlmeister I., Fischer R., Modder B., Rister M., and Schaefer H.E. Aplastic anaemia and the hypocellular myelodysplastic syndrome: histomorphological, diagnostic, and prognostic features. J Clin Pathol 38 (1985) 1218-1224
18. Toyama K., Ohyashiki K., Yoshida Y., Abe T., Asano S., Hirai H., et al. Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes. Int J Hematol 58 (1993) 53-61
19. Yoshida Y., Oguma S., Uchino H., and Maekawa T. Refractory myelodysplastic anaemias with hypocellular bone marrow. J Clin Pathol 41 (1988) 763-767
20. Kitagawa M., Kamiyama R., Takemura T., and Kasuga T. Bone marrow analysis of the myelodysplastic syndromes: histological and immunohistochemical features related to the evolution of overt leukemia. Virchows Arch B Cell Pathol 57 (1989) 47-53
21. Rios A., Canizo M.C., Sanz M.A., Vallespi T., Sanz G., Torrabadella M., et al. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. Br J Haematol 75 (1990) 26-33
22. Corey S.J., Minden M.D., Barber D.L., Kantarjian H., Wang J.C., and Schimmer A.D. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 7 (2007) 118-129
23. Dunn D.E., Tanawattanacharoen P., Boccuni P., Nagakura S., Green S.W., Kirby M.R., et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 131 (1999) 401-408